Literature DB >> 29133574

Human Papillomavirus Immunity in Oropharyngeal Cancer: Time to Change the Game?

Simon Laban1, Thomas K Hoffmann2.   

Abstract

For the first time, human papillomavirus (HPV)-specific immunity has been linked directly to the beneficial prognosis of oropharyngeal squamous cell carcinoma (OPSCC). Those patients lacking HPV immunity fare much worse. These results harbor crucial implications for future management of HPV-driven OPSCC as well as for its definition. Clin Cancer Res; 24(3); 505-7. ©2017 AACRSee related article by Welters et al., p. 634. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 29133574     DOI: 10.1158/1078-0432.CCR-17-2991

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

Review 1.  [Update on HPV-associated head and neck cancer-highlights from the 2019 ASCO Annual Meeting].

Authors:  S Tribius; N Würdemann; S Laban; T K Hoffmann; S J Sharma; J P Klussmann
Journal:  HNO       Date:  2019-12       Impact factor: 1.284

2.  Proteomes of exosomes from HPV(+) or HPV(-) head and neck cancer cells: differential enrichment in immunoregulatory proteins.

Authors:  Sonja Ludwig; Lukasz Marczak; Priyanka Sharma; Agata Abramowicz; Marta Gawin; Piotr Widlak; Theresa L Whiteside; Monika Pietrowska
Journal:  Oncoimmunology       Date:  2019-04-15       Impact factor: 8.110

Review 3.  HNSCC: Tumour Antigens and Their Targeting by Immunotherapy.

Authors:  Adrian von Witzleben; Chuan Wang; Simon Laban; Natalia Savelyeva; Christian H Ottensmeier
Journal:  Cells       Date:  2020-09-15       Impact factor: 6.600

Review 4.  Human papillomavirus genome variants and head and neck cancers: a perspective.

Authors:  Jean-Damien Combes; Silvia Franceschi
Journal:  Infect Agent Cancer       Date:  2018-04-10       Impact factor: 2.965

Review 5.  HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management.

Authors:  Matt Lechner; Jacklyn Liu; Liam Masterson; Tim R Fenton
Journal:  Nat Rev Clin Oncol       Date:  2022-02-01       Impact factor: 65.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.